← Leaderboards
David Hui
University Of Tx Md Anderson Can Ctr
$7,552,634
Attributed
$7,552,634
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,552,634 · 6
By mechanism
R01$6,699,012 · 4
R21$853,622 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Dihua Yu$18,443,603
- Isabel Torres$1,178,725
- Hoda J. Badr$6,550,695
- Kathrin Milbury$8,852,386
- Michael J Overman$2,432,364
Others in their field
Top investigators on “Quality Of Life”
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Gregory H Reaman · National Childhood Cancer Foundation$264,644,476
- David R. Weir · University Of Michigan At Ann Arbor$263,050,576
- Richard K. Wilson · Washington University$198,912,538
Research focus
Quality Of LifeEvidence BaseDistressClinical TrialsInnovationSymptomsCancer PatientDoseOutcome MeasureResponseAdverse EffectsMissionUnited States National Institutes Of HealthPatient PopulationPublic HealthPlacebosNovel TherapeuticsAffectEffective TherapyPalliationAdvanced Malignant NeoplasmPatient MonitoringPalliative CarePharmaceutical Preparations
Grant awards (19)
Strategies for Personalizing Oxygen and support Therapies for dyspnea in Oncology$665,353
R01 · FY2025 · CA · contact PI
Strategies for Personalizing Oxygen and support Therapies for dyspnea in Oncology$655,203
R01 · FY2024 · CA · contact PI
Efficacy and Safety of Rapid-Onset Opioids for Exertional Dyspnea in Cancer Patients$110,523
R01 · FY2024 · CA · contact PI
Efficacy and Safety of Rapid-Onset Opioids for Exertional Dyspnea in Cancer Patients$441,646
R01 · FY2023 · CA · contact PI
Efficacy and Safety of Rapid-Onset Opioids for Exertional Dyspnea in Cancer Patients$441,646
R01 · FY2022 · CA · contact PI
Strategies for Persistent Agitated Delirium in Palliative Care$434,388
R01 · FY2022 · CA · contact PI
Efficacy and Safety of Rapid-Onset Opioids for Exertional Dyspnea in Cancer Patients$450,660
R01 · FY2021 · CA · contact PI
Strategies for Persistent Agitated Delirium in Palliative Care$443,817
R01 · FY2021 · CA · contact PI
Efficacy and Safety of Rapid-Onset Opioids for Exertional Dyspnea in Cancer Patients$460,046
R01 · FY2020 · CA · contact PI
Strategies for Persistent Agitated Delirium in Palliative Care$444,818
R01 · FY2020 · CA · contact PI
A Randomized Controlled Trial of Dexamethasone for Dyspnea in Cancer Patients$395,140
R01 · FY2020 · CA · contact PI
Strategies for Persistent Agitated Delirium in Palliative Care$539,380
R01 · FY2019 · CA · contact PI
A Randomized Controlled Trial of Dexamethasone for Dyspnea in Cancer Patients$387,904
R01 · FY2019 · CA · contact PI
A Randomized Controlled Trial of Dexamethasone for Dyspnea in Cancer Patients$399,900
R01 · FY2018 · CA · contact PI
Palliative Therapies for Refractory Delirium in Advanced Cancer$207,611
R21 · FY2018 · NR · contact PI
A Randomized Controlled Trial of Dexamethasone for Dyspnea in Cancer Patients$428,588
R01 · FY2017 · CA · contact PI
Palliative Therapies for Refractory Delirium in Advanced Cancer$247,483
R21 · FY2017 · NR · contact PI
Adjuvant Lorazepam for Agitated Delirium in the Palliative Care Unit$181,864
R21 · FY2016 · CA · contact PI
Adjuvant Lorazepam for Agitated Delirium in the Palliative Care Unit$216,664
R21 · FY2015 · CA · contact PI